OBJECTIVES: Multiple Myeloma (MM) is a rare malignancy, accounting for only 0.8% of all cancers and 10% of hematologic malignancies. The aim of this retrospective study was to generate real world data (RWD) for MM patterns-of-care in Brazilian private healthcare system. METHODS: We searched Evidências-Kantar Health electronic claims private market database Auditron (which represents 7% of Brazilian private healthcare system) for MM patients in treatment between Mar2013-Mar2016. We retrieved data on demographics, disease stage, chemotherapy regimens, supportive treatment, stem cell transplantation (SCT) and laboratory results. Analyses were conducted using descriptive statistics. RESULTS: Our search retrieved 254 MM patients, with median age of 65 years (IQR:55-75) of which 53.9% were female. Per Durie Salmon system, 5.5% had stage I disease, 14.9% stage II and 29.5% stage III. First-line therapy data was available for 245 patients. Median treatment time was 168 days (112-224). Bortezomib-containing regimens were reported by 78.8% of patients and preferred regimen was bortezomib+cyclophosphamide+dexamethasone (VCD, 51.4%). For second-line, of 92 patients (median treatment time: 126 days (84-224), 63.5% reported bortezomib-containing regimens and preferred regimen was VCD (29.4%). For later lines, distribution of patients (number of patients, preferred regimen) was: 3^rd line (46, BCD); 4^th (23, VCD); 5^th (6, melphalan+prednisone) and 6^th(1, VCD). Forty-one patients (16.1%) received SCT in at least one line. Median age for SCT+ patients were 60 years (IQR:51-63) versus 67 years (IQR:56-77) for the non-SCT group (p<0.05). There was a significant difference between the mean time between 1st and 2nd line therapies for SCT+ (855 days; SD±455) and SCT- patients (520 days; (SD±366; p<0.05). CONCLUSIONS: RWD from Auditron database showed that bortezomib-containing regimens, especially VCD, are the preferred regimens to treat MM in most therapy lines in Brazilian private healthcare system. As expected, SCT+ patients were younger, and had longer time between 1^st and 2^nd line of therapy.